Jpmorgan Chase & CO Sellas Life Sciences Group, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding SLS
# of Institutions
37Shares Held
5.04MCall Options Held
3.27MPut Options Held
56.3K-
Vanguard Group Inc Valley Forge, PA2.29MShares$3 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$1.04 Million0.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$792,8000.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$563,7820.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$404,0903.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $26.9M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...